CN101955917A - Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein - Google Patents

Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein Download PDF

Info

Publication number
CN101955917A
CN101955917A CN 201010240974 CN201010240974A CN101955917A CN 101955917 A CN101955917 A CN 101955917A CN 201010240974 CN201010240974 CN 201010240974 CN 201010240974 A CN201010240974 A CN 201010240974A CN 101955917 A CN101955917 A CN 101955917A
Authority
CN
China
Prior art keywords
virus
particle
chimeric protein
recombinant
somatostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010240974
Other languages
Chinese (zh)
Other versions
CN101955917B (en
Inventor
侯红岩
张雪花
郑其升
侯继波
陈瑾
侯风香
薛刚
李卓
刘超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Academy of Agricultural Sciences
Original Assignee
NATIONAL CENTER FOR VETERINARY BIOLOGICALS ENGINEERING RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR VETERINARY BIOLOGICALS ENGINEERING RESEARCH filed Critical NATIONAL CENTER FOR VETERINARY BIOLOGICALS ENGINEERING RESEARCH
Priority to CN2010102409749A priority Critical patent/CN101955917B/en
Publication of CN101955917A publication Critical patent/CN101955917A/en
Application granted granted Critical
Publication of CN101955917B publication Critical patent/CN101955917B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the field of gene engineered vaccine and provides a virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein. The virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein is prepared by the following steps of: acquiring a target gene; constructing and identifying a recombined transfer vector pFast-SS4-VP2; constructing and identifying a recombined shuttle vector rBacmid-SS4-VP2; obtaining stable recombined baculovirus rBac-SS4-VP2; and infecting the rBacmid-SS4-VP2 to sf-9 insect cell to obtain a target product. The virus-like particle can be applied to preparing a vaccine for preventing porcine-infecting parvovirus and improving the growing speed of pigs, not only can prevent the porcine-infecting parvovirus, bus also can improve the growing speed of the pigs. The invention also provides application of the virus-like particle to preparing the vaccine for preventing the porcine-infecting parvovirus and improving the growing speed of the pigs.

Description

The virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein
Technical field
The present invention relates to a kind of heavy virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein, belong to the recombinant vaccine field.
Background technology
(somatostatin is a kind of braingut petide SS) to Somatostatin, is distributed widely in central nervous system and unifies in the stomach intestinal tissue, is a kind ofly can suppress the low molecule basic peptide that tethelin (GH) discharges.Brazeau etc. have isolated SS from the sheep hypothalamus, after this people have done big quantity research to generation, distribution and the biological activity of SS, and the primary structure of having measured it is one to contain 14 amino acid whose polypeptide.Mammals hypothalamus secretion somatotropin releasing factor (GHRF) and Somatostatin (SS), regulate the secretion of somatotropin (GH), and then act on target organ, as liver, produce rhIGF-1 (IGFs), thereby regulate growing of histoorgan.Because the release of GHRF stimulating growth hormone, SS suppresses the secretion of GH secretory cell, therefore, in theory, stimulate secretion or the release of GHRF or inhibition SS, perhaps simultaneously GHRF is discharged into the technological line that assassinate to swash and the release of SS is suppressed, the release that just might improve hypophysis GH secretory cell finally reaches the purpose of promotion growth of animal.
3 kinds of structural protein of pig parvoviral (PPV) genome encoding are respectively VP1, VP2, VP3.Wherein VP2 is the main capsid protein that constitutes virus particle; have hemagglutination activity, account for 80% of viral capsid proteins total amount, VP2 albumen carries main antigenic determinant; can induce body to produce the protectiveness neutralizing antibody, VP2 to virus infection, bring into play its pathogenic aspect and also play a crucial role.VP2 albumen can independently assemble when vivoexpression, can form complete virus-like particle automatically, has good immunogenicity, becomes the main direction of virus vaccines research.Virus-like particle (virus-like particles VLPs) is the hollow bead that one or more structural protein of certain virus are assembled into, it had both had the stability and the immunogenicity of similar natural viral, possesses the potential that carries foreign protein or polypeptide again, the nucleic acid that does not contain virus does not have infectivity, makes it be expected to become the good carrier that makes up polyvalent vaccine.
Summary of the invention
The purpose of this invention is to provide a kind of virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein, can prevent pig to infect parvovirus and can improve growth speed of pigs again; The present invention provides the application of this virus-like particle in the vaccine of preparation prevention pig infection parvovirus, raising growth speed of pigs simultaneously.
The invention provides the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein, get by following method preparation:
(1) obtains goal gene: adopt forward primer P1 and reverse primer P2 amplification pig parvoviral VP2 gene, adopt artificial synthesis to obtain the gene order that 4 Somatostatins that copy of restriction enzyme site have been added at two ends respectively, the gene order of the Somatostatins of described 4 copies is SS4;
The sequence of described forward primer P1 is:
5’-cgggatccagccggctgcaagaacttcttctggaagaccttcacctcctgcactgaattgtctgca-3’,
The sequence of described reverse primer P2 is:
5’-cgcctcgagctagtataattttcttggtat-3’;
(2) make up and identify recombinant transfer vector pFast-SS4-VP2;
(3) make up and identify recombinant shuttle vector rBacmid-SS4-VP2;
(4) obtain stable recombinant baculovirus rBac-SS4-VP2;
(5) described viral rBac-SS4-VP2 is infected the sf-9 insect cell, obtain to contain the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein.
Gene order 5 ' the end of described 4 copy Somatostatins adds BamH I restriction enzyme site, 3 ' end adds Bg lII restriction enzyme site.
Described recombinant transfer vector pFast-SS4-VP2 structure of step (2) and authentication method are as follows: the VP2 gene clone to transfer vector pFastBac HT A, is cut through enzyme, and positive plasmid called after pFast-VP2 is identified in order-checking; This plasmid pFast-VP2 cuts, is connected with SS4 behind the dephosphorylation through enzyme, cuts through enzyme again, and order-checking, being accredited as the male plasmid is recombinant transfer vector pFast-SS4-VP2.
Structure and the authentication method of step (3) recombinant shuttle vector rBacmid-SS4-VP2 are: recombinant vectors pFast-SS4-VP2 is transformed among the competent cell DH10Bac that into contains shuttle plasmid Bacmid, be accredited as the male plasmid through the screening of the white bacterium colony of indigo plant and PCR and be recombinant shuttle vector rBacmid-SS4-VP2; Adopt the baculovirus universal primer during described PCR identifies, upstream primer is GTTTTCCCAGTCACGAC, and downstream primer is CAGGAAACAGCTATGAC.
The method that step (4) obtains stable recombinant baculovirus rBac-SS4-VP2 is: recombinant shuttle vector rBacmid-SS4-VP2 transfection sf-9 insect cell, carry out the amplification of recombinant baculovirus, extract the genomic dna of the recombinant baculovirus after increasing, be accredited as positive person through PCR and be stable recombinant baculovirus rBac-SS4-VP2; Primer during described PCR identifies is primer P1 and P2.
With described viral rBac-SS4-VP2 inoculation sf-9 insect cell, collect the sf-9 insect cell of pathology in the step (5), centrifugal with carrying out after this sick cell fragmentation, obtain supernatant liquor, adopt ammonium sulfate precipitation method to carry out albumen precipitation; Described albumen precipitation is suspended in the damping fluid, desalination behind the inactivation of viruses rBacmid-SS4-VP2, ultrafiltration obtains the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein.
The present invention also provides the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein to infect the application of the vaccine of parvovirus, raising growth speed of pigs preparation prevention pig.
The present invention contains the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein, can prevent pig to infect parvovirus and can improve growth speed of pigs again; As antigen, with white oil or aluminium glue a vaccine immunity cleaning level mouse, can detect higher pig parvoviral antibody with this virus-like particle behind the booster immunization 2 weeks as adjuvant, behind the booster immunization during 4 weeks antibody rise to the highest; The content of tethelin and Insulin-Like cytokine obviously raises in the serum of immunity back, and promptly the chimeric protein of Biao Daing has been brought into play the effect that promotes body growth.Virus-like particle of the present invention can prevent pig parvoviral safely and effectively, improve growth speed of pigs.
Four description of drawings
Fig. 1 is the electrophorogram after the BamH I of recombinant plasmid pFast-SS4-VP2 and Xho I enzyme are cut, and among the figure: M-Marker DL2000,1-enzyme cut back recombinant plasmid pFast-SS4-VP2.
Fig. 2 is rBacmid-SS 4The electrophorogram that the PCR of-VP2 identifies is among the figure: M-Marker DL15000,1-rBacmid-pFast; 2-rBacmid-SS4-VP2.
Fig. 3 is rBac-SS 4The electrophorogram that the genomic PCR of-VP2 identifies is among the figure: 1-rBac-SS 4-VP2 genome, M-Marker DL2000
Fig. 4 is the SDS-PAGE electrophorogram that obtains recombinant protein SS4-VP2 under the different infection multiplicity conditions, among the figure:
1-empty carrier Bacmid, 2-infection multiplicity 0.01,3-infection multiplicity 0.05,4-infection multiplicity 0.1,5-infection multiplicity 0.5, M-molecular weight of albumen standard.
Fig. 5 is the Western-blotting electrophorogram of chimeric protein SS4-VP2, and among the figure: 1-0.2MOI infects the Sf9 cell and obtains albumen, 2-0.5MOI infection Sf-9 cell acquisition albumen, and 3-wild virus infection Sf9 cell obtains albumen, M-molecular weight of albumen standard.
A figure among Fig. 6 is indirect immunofluorescence (IFA) the detection figure that rBacmid-SS4-VP2 infects the sf-9 cell, and B figure is the IFA detection figure that empty carrier Bacmid infects the sf-9 cell, and C figure is the IFA detection figure of normal sf-9 cell.
A figure among Fig. 7 is the electron microscopic observation figure after rBacmid-SS4-VP2 infects the sf-9 cell, and B figure is the electron microscopic observation figure after empty carrier Bacmid infects the sf-9 cell.
Fig. 8 represents the blood-serum P PV antibody horizontal of different immunity each test group in period.
Fig. 9 represents the serum Somatostatin antibody horizontal of different immunity each test group in period.
Figure 10 represents the Serum GH level of each test group of different times.
Five embodiments
Embodiment 1 contains the preparation of the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein
1) acquisition of goal gene
(accession number: AY781130), design two primers with Primer Premier 5.0 biosoftwares, the vp2 gene of the PPV NJ-1 strain of announcing with reference to GenBank is used to increase the full gene of VP2.
Forward primer P1 is:
5’-cgggatccagccggctgcaagaacttcttctggaagaccttcacctcctgcactgaattgtctgca-3’
Reverse primer P2 is:
5’-cgcctcgagctagtataattttcttggtat-3’
Add BamHI and XhoI restriction enzyme site respectively, DNA with PPV NJ-1 strain is a template, with P1, P2 is a primer amplification VP2 complete genome sequence, reclaims at 1% agarose gel electrophoresis, is connected into the pMD18-T carrier, transformed competence colibacillus intestinal bacteria E.coli DH5 α, alkaline lysis method of extracting plasmid, enzyme are cut and are checked order and identify correctly, acquisition positive plasmid pMD18T-VP2.
Somatostatin (SS) the gene order SS4 of 4 copies is: AAAAAGCTGGTTGTAAGAACTTTTTTTGGAAGACTTTTACTTCTTGTGCTGGTTGT AAGAACTTTTTTTGGAAGACTTTTACTTCTTGTGCTGGTTGTAAGAACTTTTTTTG GAAGACTTTTACTTCTTGTGCTGGTTGTAAGAACTTTTTTTGGAAGACTTTTACTT CTTGT.5 ' end at SS4 adds BamH I restriction enzyme site, 3 ' end adds Bg l II restriction enzyme site, adopts the artificial synthesis preparation then.
2) recombinant transfer vector pFast-SS4-VP2 makes up and identifies
Use BamH I and Xho I double digestion plasmid pMD18T-VP2 and transfer vector pFastBac HT A respectively, behind VP2 fragment and transfer vector pFastBac HT A purifying, connect with the T4DNA ligase enzyme, transform DH5 α competent cell, the alkaline lysis method of extracting plasmid, BamH I and Xho I double digestion and order-checking are identified, with positive plasmid called after pFast-VP2.Somatostatin (SS) gene of 4 copies is cut with BamH I and Bg l II enzyme, with pFast-VP2 BamH I single endonuclease digestion, be connected with Somatostatin (SS4) gene of T4DNA ligase enzyme behind the dephosphorylation with 4 copies, transform DH5 α competent cell, the alkaline lysis method of extracting plasmid, with BamH I and Blg II double digestion, the appearance size is the fragment about 1900bp on the electrophorogram, the positive plasmid of this plasmid then, called after pFast-SS4-VP2 is recombinant transfer vector pFast-SS4-VP2 (seeing the numbering 1 among Fig. 1).
3) structure of recombinant shuttle vector rBacmid-SS4-VP2 and evaluation
Recombinant transfer vector pFast-SS4-VP2 is transformed the 100 μ l DH10Bac competent cells that into contain shuttle plasmid Bacmid, and the screening flat board (containing gentamicin, kantlex and tetracyclin resistance) of coating X-Gal/IPTG, 37 ℃ of incubators are inverted lucifuge and are cultivated 36-48h, and extremely blue white bacterium colony occurs.X-Gal/IPTG (Kan/Tet/Gen) flat board is placed 4 ℃ of refrigerator 30min, bacterium colony is fully developed the color, select white single bacterium colony, be inoculated in and contain in the three LB liquid nutrient mediums that resist, overnight incubation, coating X-Gal/IPTG/ (Kan/Tet/Gen) flat board so carries out three blue hickie screenings, extract the Bacmid of reorganization by the alkaline lysis of improveing in the Bac-to-Bac baculovirus expression system specification sheets, with the baculovirus universal primer reorganization Bacmid that is extracted carried out PCR and identify:
Upstream primer: GTTTTCCCAGTCACGAC
Downstream primer: CAGGAAACAGCTATGAC
The amplified fragments size is the plasmid about 4300bp, is positive plasmid, and called after rBacmid-SS4-VP2 is recombinant shuttle vector rBacmid-SS4-VP2 (seeing the numbering 2 among Fig. 2).
4) obtain stable recombinant baculovirus rBac-SS4-VP2:
According to Lipofectamine TMThe description operation of 2000 transfection reagents, sf-9 cell with recombinant shuttle vector rBacmid-SS4-VP2 transfection logarithmic phase, 27 ℃ leave standstill more than the cultivation 3d, collect sick cell, recombinant baculovirus genomic dna after Proteinase K-SDS-phenol/chloroform extraction amplification is identified through VP2 Auele Specific Primer P1, P2, and the amplified fragments size is the stable recombinant virus that is about 1900bp, called after rBac-SS4-VP2 is recombinant baculovirus rBac-SS4-VP2 (seeing the numbering 1 among Fig. 3);
5) acquisition contains the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein:
Amplification rBac-SS4-VP2, inoculation sf-9 insect cell, cultivate the sf-9 insect cell that pathology is collected in the back, behind the ultrasonic treatment, the centrifugal 15min of 10000rpm collects supernatant (the chimeric protein SS4-VP2 that contains expression in the supernatant liquor), add the pH7.0 saturated ammonium sulphate to final concentration 20%, 4 ℃ of stirrings are spent the night and are precipitated, and the centrifugal 10min of 18000rpm is resuspended in precipitation among the PBS then.Add Triton X-100 to 1% of enriched material volume, Tributyl phosphate (TBP is a tributyl phosphate) is used for inactivation of viruses rBacmid-SS4-VP2 to 0.3% of enriched material volume.The desalination of dialysing behind the static 30min of room temperature, centrifugal with the ultrafiltration of ultrafiltration pipe again, remove foreign protein, obtain chimeric protein SS4-VP2, promptly obtained the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein.
6) evaluation of the virus-like particle of chimeric protein
1. recombinant protein SDS-PAGE identifies and the Western-Blot evaluation
With rBacmid-SS4-VP2 respectively with different infection multiplicity (MOI) 0.01,0.05,0.1,0.5 infect the Sf-9 cell, 96h collects pathology Sf-9 insect cell, after PBS washing 3 times, add that the sample damping fluid boils 10min, after carrying out the SDS-PAGE electrophoresis, Coomassie brilliant blue dyeing, found that (see figure 4), at lane2, lane3, lane4, lane5 (the corresponding infection multiplicity 0.01 of difference, 0.05,0.1,0.5) in the specific protein band that a size is about 64kD all appears, with target protein molecular weight basically identical, and this protein belt does not appear in empty carrier contrast Bacmid (lane1), several infection ratios do not have tangible difference, prove that the chimeric protein (SS4-VP2) that contains pig parvoviral VP2 and Somatostatin has obtained expression.
Is 0.2,0.5 cells infected with rBacmid-SS4-VP2 with MOI, preparation contains the chimeric protein SS4-VP2 of pig parvoviral VP2 and Somatostatin, and carry out the SDS-PAGE electrophoresis, be transferred to nitrocellulose filter after, spend the night with the PBST sealing that contains 10% (mass concentration) skimming milk; Pig VP2 protein positive serum (Wuhan Keqian Animal Biological Products Co., Ltd.) the room temperature effect 2h that adds dilution in 1: 100; PBST washs three times, adds goat-anti pig IgG-HRP (Beijing Bo Aosen Bioisystech Co., Ltd) room temperature effect 2h of 1: 2000 times of dilution; It is inferior to give a baby a bath on the third day after its birth, and differential protein band (Fig. 5) is observed in DAB (diaminobenzidine) colour developing.The result show utilize the baculovirus vivoexpression SS4-VP2 albumen can with pig VP2 protein positive serum generation specific immune response, the chimeric protein of expression has biologic activity.
2. indirect immunofluorescence detects
With empty carrier Bacmid, rBacmid-SS4-VP2 infects the sf-9 insect cell of logarithmic phase growth respectively, treat that cell produces pathology fully after, outwell supernatant, with the alcohol fixation 40-60min of 75% (volumetric concentration); Wash natural air drying 3 times with the PBS that contains 1% (mass concentration) BSA; Add the pig parvoviral VP2 albumen cavy positive serum (with wild baculovirus protein effect) of dilution in 1: 100,37 ℃ of wet boxes are hatched 2h; Wash natural air drying 3 times with the PBS that contains 1% (mass concentration) BSA; The goat-anti cavy two anti-(Beijing Bo Aosen Bioisystech Co., Ltd) that adds FITC (fluorescein isothiocyanate) mark of dilution in 1: 50,37 ℃ of effect 30min; Wash 3 times natural air drying with the PBS that contains 1%BSA (mass concentration); Fluorescent microscope is observed down, and the result shows the visible very strong green fluorescence (A in the corresponding diagram 6) corresponding to the Electronic Speculum result of rBacmid-SS4-VP2, and reason is recombinant protein SS4-VP2 and pig parvoviral VP2 albumen cavy positive serum specific reaction; And empty carrier Bacmid (B in the corresponding diagram 6) fluorescence is very weak, and normal sf-9 cell does not have fluorescence (C in the corresponding diagram 6).The result shows that rBac-SS4-VP2 has obtained expression in the sf-9 cell.
3. electron microscopic observation virus-like particle
Is 0.05 infection Sf-9 cell with rBacmid-SS4-VP2 with MOI, 120h treats to receive poison after the complete pathology of cell, it is inferior to give a baby a bath on the third day after its birth with PBS, 2000rpm centrifugation cell 10min, 2.5% (volumetric concentration) glutaraldehyde stationary liquid (0.1mol/mL phosphoric acid buffer, pH 7.4, contain 2.5% glutaraldehyde) fixedly spends the night for 4 ℃, do ultrathin section(ing), electron microscopic observation.Found that in cell, have flock together, diameter is the spheroidal particle of 20~30nm, this particulate form, size all close with the totivirus particle of PPV (A among Fig. 7 schemes) are the virus-like particles (CVLP) that is formed by the SS4-VP2 chimeric protein.Empty carrier Bacmid infects the electron microscopic observation of Sf9 cell, does not see identical virus particle (the B figure among Fig. 7).
The immunogenicity evaluation of the virus-like particle of embodiment 2 chimeric proteins
(1) immune programme for children
Choose 60 of cleaning level mouse, be divided into 4 groups at random.Each test group antigen, adjuvant and immunization ways such as following table:
Figure BSA00000211125300071
Immunity twice, each 2 weeks at interval, eyeball of mouse blood sampling weekly after the immunity, conventional separation of serum ,-20 ℃ of preservations are stand-by.
(2) detection of pig parvoviral ELISA antibody (being PPV antibody)
Use the antibody in pig parvoviral ELISA antibody assay kit (Wuhan Keqian Animal Biological Products Co., Ltd.) the detection serum.1: 40 dilution back of serum is added in the microwell plate of pre-bag quilt, and every hole adds 100 μ L.Same 1: 3 dilution positive and negative control serums (PPV negative antibody, the positive), 2 holes, every hole 100 μ L are respectively established in the positive and negative contrast.Other establishes a blank hole, and the blank hole adds 100 μ L diluents.37 ℃ of incubation 30min; After washing 3 times, every hole adds sheep anti-mouse igg-HRP 100 μ L of 1: 20000 times of dilution, 37 ℃ of incubation 1h; After washing 3 times, every hole adds substrate A liquid, each one of B liquid (being in the test kit), mixing room temperature lucifuge colour developing 10min; Every hole adds one of stop buffer, measures OD in the 10min 630The test-results (see figure 8) shows that the SS4-VP2 of baculovirus expression produces higher ELISA antibody, and the effect of aluminium glue adjuvant is better than white-oil adjuvant, and the antibody that the totivirus inactivated vaccine produces is the highest.
(3) Somatostatin (SS) antibody ELISA detected result
By elisa plate, 100 μ L/ holes are exempted from 1 week of back, 3 weeks, 5 all mice serums with two and are carried out dilution in 1: 100, detect Somatostatin antibody horizontal in the serum with synthetic peptide (the 5 μ g/mL) bag of Somatostatin.(see figure 9) is as a result: immune recombinant protein SS4-VP2/ aluminium glue group, and SS4-VP2/ white oil group has produced specific antibody in the test later stage, and PPV control group and PBS group do not have specific antibody to produce.SS4-VP2/ aluminium glue group antibody horizontal is the highest.Illustrate that SS4-VP2 antigen has good immunogenicity, produce the Somatostatin antibody of higher level, wherein aluminium adjuvant is better than white-oil adjuvant to antigenic immuno-potentiation.
(4) detection of tethelin (GH)
Adopt radioimmunoassay (detection of Nanjing Military Command hospital general) to measure two and exempt from GH level in 2 weeks of back, the 4 all mice serums.The result shows (see figure 10), and two exempt from the back during 2 weeks, and SS4-VP2/ aluminium glue (II group), SS4-VP2/ white oil (I group) test group Serum GH level are apparently higher than PBS (IV group) and PPV deactivation vaccine (III group) test group; Two exempted from for 4 whens week, and SS4-VP2/ aluminium glue (II group), SS4-VP2/ white oil (I group) test group Serum GH level slightly descend, and PBS (IV group) and PPV deactivation vaccine (III group) test group slightly raise.Wherein II group (SS4-VP2/ aluminium glue) test group Serum GH level is higher, the specific antibody of anti-SS that SS4-VP2/ aluminium glue, SS4-VP2/ white oil test group the produce endogenic SS of part that neutralized is described, thereby the concentration of tethelin is raise, the growth that this helps promoting experimental animal to a certain extent reaches somatotrophic purpose.
Figure ISA00000211125500011
Figure ISA00000211125500021

Claims (7)

1. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein is got by following method preparation:
(1) obtains goal gene: adopt forward primer P1 and reverse primer P2 amplification pig parvoviral VP2 gene, adopt artificial synthesis to obtain the gene order that 4 Somatostatins that copy of restriction enzyme site have been added at two ends respectively, the gene order of the Somatostatins of described 4 copies is SS4;
The sequence of described forward primer P1 is:
5’-cgggatccagccggctgcaagaacttcttctggaagaccttcacctcctgcactgaattgtctgca-3’,
The sequence of described reverse primer P2 is:
5’-cgcctcgagctagtataattttcttggtat-3’;
(2) make up and identify recombinant transfer vector pFast-SS4-VP2;
(3) make up and identify recombinant shuttle vector rBacmid-SS4-VP2;
(4) obtain stable recombinant baculovirus rBac-SS4-VP2;
(5) described viral rBac-SS4-VP2 is infected the sf-9 insect cell, obtain to contain the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein.
2. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein according to claim 1 is characterized in that the gene order 5 ' end of described 4 copy Somatostatins adds BamH I restriction enzyme site, 3 ' end adds Bg l II restriction enzyme site.
3. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein according to claim 1 and 2, it is characterized in that (2) described recombinant transfer vector pFast-SS4-VP2 makes up and authentication method is as follows: with the VP2 gene clone to transfer vector pFastBac HTA, cut through enzyme, positive plasmid called after pFast-VP2 is identified in order-checking; This plasmid pFast-VP2 cuts, is connected with SS4 behind the dephosphorylation through enzyme, cuts through enzyme again, and order-checking, being accredited as the male plasmid is recombinant transfer vector pFast-SS4-VP2.
4. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein according to claim 3, the structure and the authentication method that it is characterized in that described (3) recombinant shuttle vector rBacmid-SS4-VP2 are: recombinant vectors pFast-SS4-VP2 is transformed among the competent cell DH10Bac that into contains shuttle plasmid Bacmid, be accredited as the male plasmid through the screening of the white bacterium colony of indigo plant and PCR and be recombinant shuttle vector rBacmid-SS4-VP2; Adopt the baculovirus universal primer during described PCR identifies, upstream primer is GTTTTCCCAGTCACGAC, and downstream primer is CAGGAAACAGCTATGAC.
5. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein according to claim 4, the method that it is characterized in that the recombinant baculovirus rBac-SS4-VP2 that step (4) acquisition is stable is: recombinant shuttle vector rBacmid-SS4-VP2 transfection sf-9 insect cell, carry out the amplification of recombinant baculovirus, extract the genomic dna of the recombinant baculovirus after increasing, be accredited as positive person through PCR and be stable recombinant baculovirus rBac-SS4-VP2; Primer during described PCR identifies is primer P1 and P2.
6. the virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein according to claim 5, it is characterized in that in the step (5) described viral rBac-SS4-VP2 inoculation sf-9 insect cell, collect the sf-9 insect cell of pathology, centrifugal with carrying out after this sick cell fragmentation, obtain supernatant liquor, adopt ammonium sulfate precipitation method to carry out albumen precipitation; Described albumen precipitation is suspended in the damping fluid, desalination behind the inactivation of viruses rBacmid-SS4-VP2, ultrafiltration obtains the virus-like particle of pig parvoviral VP2 and Somatostatin chimeric protein.
7. application that each described virus-like particle that contains pig parvoviral VP2 and Somatostatin chimeric protein infects parvovirus, improves the vaccine of growth speed of pigs preparation prevention pig in the claim 1~6.
CN2010102409749A 2010-07-30 2010-07-30 Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein Expired - Fee Related CN101955917B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010102409749A CN101955917B (en) 2010-07-30 2010-07-30 Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010102409749A CN101955917B (en) 2010-07-30 2010-07-30 Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein

Publications (2)

Publication Number Publication Date
CN101955917A true CN101955917A (en) 2011-01-26
CN101955917B CN101955917B (en) 2012-08-22

Family

ID=43483505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010102409749A Expired - Fee Related CN101955917B (en) 2010-07-30 2010-07-30 Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein

Country Status (1)

Country Link
CN (1) CN101955917B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321634A (en) * 2011-08-31 2012-01-18 中国农业科学院生物技术研究所 Preparation method of mink enteritis parvovirus empty capsid antigen particles
CN102382845A (en) * 2011-10-14 2012-03-21 中国农业科学院生物技术研究所 Method for producing porcine parvovirus antigen and its product
CN103033622A (en) * 2011-12-26 2013-04-10 武汉中博生物股份有限公司 PCV2 (porcine circovirus 2) ELISA (enzyme-linked immuno sorbent assay) antigen detection kit as well as preparation method and applications thereof
CN107142235A (en) * 2017-06-20 2017-09-08 江西嘉博生物工程有限公司 A kind of restructuring Brevibacillus brevis for expressing pig growth hormone gene and construction method and application
CN107868131A (en) * 2017-10-13 2018-04-03 长春西诺生物科技有限公司 A kind of porcine parvovirus subunit vaccine and preparation method thereof
CN111793650A (en) * 2020-07-08 2020-10-20 中国农业科学院兰州兽医研究所 Preparation method and application of chimeric south Africa type 2 foot-and-mouth disease virus multi-epitope gene porcine parvovirus H-like particle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101289657A (en) * 2008-03-28 2008-10-22 江苏省农业科学院 Recombination porcine parvovirus VP2 virus particles for expressing exogenous gene
CN101289658A (en) * 2008-03-28 2008-10-22 江苏省农业科学院 Recombination virus particles for expressing 2-typed porcine circovirus nucleocapsid protein Cap gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101289657A (en) * 2008-03-28 2008-10-22 江苏省农业科学院 Recombination porcine parvovirus VP2 virus particles for expressing exogenous gene
CN101289658A (en) * 2008-03-28 2008-10-22 江苏省农业科学院 Recombination virus particles for expressing 2-typed porcine circovirus nucleocapsid protein Cap gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
《vaccine》 20080313 Qunxing Pan 等 Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2 2119-2126 1-7 第26卷, 第17期 2 *
《中国病毒学》 20060331 司艳红 等 猪细小病毒vp2基因的表达和类病毒颗粒的构建 148-152 1-7 第21卷, 第2期 2 *
《微生物学报》 20021231 吕建强 等 猪细小病毒VP2蛋白在昆虫细胞中的表达及其特性 675-679 1-7 第42卷, 第6期 2 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321634A (en) * 2011-08-31 2012-01-18 中国农业科学院生物技术研究所 Preparation method of mink enteritis parvovirus empty capsid antigen particles
CN102321634B (en) * 2011-08-31 2014-02-12 中国农业科学院生物技术研究所 Preparation method of mink enteritis parvovirus empty capsid antigen particles
CN102382845A (en) * 2011-10-14 2012-03-21 中国农业科学院生物技术研究所 Method for producing porcine parvovirus antigen and its product
CN102382845B (en) * 2011-10-14 2014-01-29 中国农业科学院生物技术研究所 Method for producing porcine parvovirus antigen and its product
CN103033622A (en) * 2011-12-26 2013-04-10 武汉中博生物股份有限公司 PCV2 (porcine circovirus 2) ELISA (enzyme-linked immuno sorbent assay) antigen detection kit as well as preparation method and applications thereof
CN103033622B (en) * 2011-12-26 2015-03-25 武汉中博生物股份有限公司 PCV2 (porcine circovirus 2) ELISA (enzyme-linked immuno sorbent assay) antigen detection kit as well as preparation method and applications thereof
CN107142235A (en) * 2017-06-20 2017-09-08 江西嘉博生物工程有限公司 A kind of restructuring Brevibacillus brevis for expressing pig growth hormone gene and construction method and application
CN107868131A (en) * 2017-10-13 2018-04-03 长春西诺生物科技有限公司 A kind of porcine parvovirus subunit vaccine and preparation method thereof
CN111793650A (en) * 2020-07-08 2020-10-20 中国农业科学院兰州兽医研究所 Preparation method and application of chimeric south Africa type 2 foot-and-mouth disease virus multi-epitope gene porcine parvovirus H-like particle

Also Published As

Publication number Publication date
CN101955917B (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CN101955917B (en) Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein
CN103260645B (en) As norovirus housing and rotavirus vp 6 albumen of combined vaccine
CN113337478B (en) Cat parvovirus strain and application thereof
CN101289658A (en) Recombination virus particles for expressing 2-typed porcine circovirus nucleocapsid protein Cap gene
CN101914503B (en) Canine distemper attenuated vaccine strain and application thereof
CN114854697B (en) Trivalent inactivated vaccine of porcine rotavirus G4-G5-G9 and preparation method and application thereof
CN102352347A (en) Porcin circovirus type 2 (PCV2) recombinant baculovirus construction method and subunit vaccine preparation method thereof
CN116217678B (en) Virus-like particle vaccine for resisting H5N1 subtype avian influenza and preparation method and application thereof
CN103509761B (en) Recombinant porcine pseudorabies virus strain used for expression of porcine circovirus type II (PCV2) ORF2 gene, and preparation method thereof
CN114561366B (en) Goat kuraria virus isolate and application thereof
CN103387996A (en) Canine parvovirus-like particles and preparation method and application thereof
CN101289657A (en) Recombination porcine parvovirus VP2 virus particles for expressing exogenous gene
CN101914502B (en) I-type canine adenovirus attenuated vaccine strain and application thereof
CN117431200A (en) Recombinant bacillus subtilis for displaying Newcastle disease virus HN protein on spore surface, construction method and application
CN101979502A (en) Recombinant brucella expressing VP1 gene of O-type foot-and-mouth disease virus and method for producing vaccines thereof
CN105802918B (en) Chicken's infectious bronchitis nephritis strain and its vaccine composition, preparation method and application
CN110559433B (en) Avian influenza virus-like particle vaccine, and preparation method and application thereof
CN102363770A (en) Recombinant baculovirus capable of expressing porcine circovirus type 2 Cap protein and somatostatin in fusion manner, and subunit vaccine thereof
CN101979503A (en) Recombinant brucella for expressing Asia type-I foot and mouth disease virus VP1 genes and method for producing vaccines thereof
CN109694857A (en) Express recombinant baculovirus and its application of 3 type Cap protein of pig circular ring virus
CN109022373A (en) The end of duck plague virus UL56 gene 3 ' missing and LORF5 gene deletion mutants and its construction method and application
CN1225553C (en) Recombinant pseudo-rabies virus expressing swine parvovirus VP2 gene and vacine and its preparation method
CN114921422A (en) Canine-derived feline parvovirus isolate and application thereof
CN103820398B (en) A kind of mink enteritis virus recombinant subunit vaccine and preparation method thereof
CN106636013A (en) Ankara virus strain FAdV-HB and preparation and application of inactivated vaccine of ankara virus strain FAdV-HB

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NANJING TIANBANG BIO-INDUSTRY CO., LTD.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20110815

Address after: Xiaolingwei Nanjing City, Jiangsu province 210014 Zhongling Street No. 50

Applicant after: National Center for Veterinary Biologicals Engineering Research

Co-applicant after: NANJING TIANBANG BIO-INDUSTRY Co.,Ltd.

Address before: Xiaolingwei Nanjing City, Jiangsu province 210014 Zhongling Street No. 50

Applicant before: National Center for Veterinary Biologicals Engineering Research

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES

Free format text: FORMER OWNER: NATIONAL RESEARCH CENTER OF VETERINARY BIOLOGICALS ENGINEERING AND TECHNOLOGY

Effective date: 20140113

Free format text: FORMER OWNER: NANJING TIANBANG BIO-INDUSTRY CO., LTD.

Effective date: 20140113

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140113

Address after: Xiaolingwei Nanjing City, Jiangsu province 210014 Zhongling Street No. 50

Patentee after: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES

Address before: Xiaolingwei Nanjing City, Jiangsu province 210014 Zhongling Street No. 50

Patentee before: National Center for Veterinary Biologicals Engineering Research

Patentee before: NANJING TIANBANG BIO-INDUSTRY Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

Termination date: 20210730

CF01 Termination of patent right due to non-payment of annual fee